#USA #Nashville #Teoxane #Revance #RHA Redensity Eye

Revance and Teoxane Announce FDA Approval of RHA Redensity Eye

In a significant leap for aesthetic treatments, Revance and Teoxane have declared the FDA approval of RHA Redensity Eye, a novel solution specifically designed to address moderate to severe tissue volume loss in the under-eye area. This innovative product, derived from the Teoxane RHA® Collection, promises to deliver natural-looking results that can last up to 12 months when injected into the infraorbital hollows of adults aged 22 and older.

The under-eye region, known for its complexity and expressiveness, presents unique challenges in achieving aesthetic harmony. Therefore, the selection of appropriate fillers is crucial. RHA Redensity Eye features a uniquely optimized rheological profile, ensuring it offers unsurpassed dynamic strength and stretch compared to other hyaluronic acid fillers available on the market. Powered by Teoxane’s proprietary Preserved Network Technology (PNT), this product uses a gentle, heatless manufacturing approach that preserves the natural structural integrity of hyaluronic acid.

Key Features of RHA Redensity Eye

• - Enhanced Longevity: The filler is designed to adapt to the delicate dynamics of the under-eye area, maintaining its effect for up to a year.
• - Safety Assurance: This approval follows a positive outcome from a 52-week pivotal clinical study assessing its safety and efficacy. Approximately 93% of participants noted aesthetic improvements after three months, and these results persisted without the need for touch-ups for up to a year.
• - Patient-Centric Outcomes: RHA Redensity Eye is the first hyaluronic acid gel approved in the USA for the infraorbital area, using patient-reported results as a primary endpoint in its clinical trial. Notably, it exhibited a favorable safety profile, with no serious treatment-related adverse effects observed.

“Achieving optimal results in the periorbital zone is challenging,” explains Madame Valérie Taupin, the CEO and founder of Teoxane. “RHA Redensity Eye's unique properties, including its spreadability and soft profile, perfectly meet the requirements of this complex anatomical region.”

The demand for improvements in the under-eye area is especially pronounced among individuals undergoing GLP-1 therapies, known to lead to volume loss in this region. Thus, the approval of RHA Redensity Eye responds to an increasing need for targeted aesthetic solutions that address such changes.

Dr. Joely Kaufman-Janette, a board-certified dermatologist involved in the clinical trials, emphasized the significance of this new option. “As a practitioner, I've long sought a filler that can meet the specific challenges presented by the under-eye area,” she noted, expressing optimism about offering this new treatment to her patients.

RHA Redensity Eye adds strength to the already successful Teoxane RHA Collection, which made its mark with prior innovations such as the introduction of mepivacaine in August 2025 and RHA Dynamic Volume in March 2026. The continuous expansion of this product line demonstrates Revance’s commitment to delivering clinically proven solutions that enhance natural beauty and restore patients' confidence.

As more patients seek safe and effective options for under-eye rejuvenation, RHA Redensity Eye stands poised to fulfill that demand, redefining standards in aesthetic treatments. For more information about the Teoxane RHA Collection, you can visit rha.revanceaesthetics.com.

About Revance and Teoxane

Revance is a global leader in aesthetics and skincare, specializing in transformative treatment options, while Teoxane has over two decades of experience in hyaluronic acid solutions, paving the way in aesthetic medicine. Together, they aim to enhance the capabilities of modern aesthetics, focusing on innovative, effective, and patient-centric approaches.